439 related articles for article (PubMed ID: 16012715)
1. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
2. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
3. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
O'Kane SL; Cawkwell L; Campbell A; Lind MJ
Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
[TBL] [Abstract][Full Text] [Related]
6. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
[TBL] [Abstract][Full Text] [Related]
7. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
8. Expression of vascular endothelial growth factor in malignant mesothelioma.
Aoe K; Hiraki A; Tanaka T; Gemba K; Taguchi K; Murakami T; Sueoka N; Kamei T; Ueoka H; Sugi K; Yoshino T; Kishimoto T
Anticancer Res; 2006; 26(6C):4833-6. PubMed ID: 17214348
[TBL] [Abstract][Full Text] [Related]
9. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
10. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
Flores RM; Routledge T; Seshan VE; Dycoco J; Zakowski M; Hirth Y; Rusch VW
J Thorac Cardiovasc Surg; 2008 Sep; 136(3):605-10. PubMed ID: 18805259
[TBL] [Abstract][Full Text] [Related]
11. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
Sherman ME; Mark EJ
Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma: surgical management in 285 patients.
Schipper PH; Nichols FC; Thomse KM; Deschamps C; Cassivi SD; Allen MS; Pairolero PC
Ann Thorac Surg; 2008 Jan; 85(1):257-64; discussion 264. PubMed ID: 18154820
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
15. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.
Strizzi L; Muraro R; Vianale G; Natoli C; Talone L; Catalano A; Mutti L; Tassi G; Procopio A
J Pathol; 2002 Jun; 197(2):218-23. PubMed ID: 12015746
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
17. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
Fusco V; Ardizzoni A; Merlo F; Cinquegrana A; Faravelli B; De Palma M; Chessa L; Nicolò G; Serra M; Capaccio A
Anticancer Res; 1993; 13(3):683-9. PubMed ID: 8317897
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
[TBL] [Abstract][Full Text] [Related]
20. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
